Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LUTARTERIAL intra-arterial hepatic PRRT in GEP-NET
2024-514785-39-00Phase 2Authorised
- Sponsor
- Centre Hospitalier Universitaire de Bordeaux
- Start
- Nov 2024
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lutetium Lu 177 dotatate in Gastroenteropancreatic Carcinoid Tumor, sponsored by Centre Hospitalier Universitaire de Bordeaux. Primary endpoint: 68Ga-DOTA-peptides uptake in liver metastases after intra-hepatic injection. Planned start Nov 2024; status: authorised.
02
Drugs
lutetium Lu 177 dotatate
03
Conditions
Gastroenteropancreatic Carcinoid Tumor
Beyond the preview
Go deeper on 2024-514785-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514785-39-00.